How to identify actionable biomarkers from the plasma proteome

In a study published in Neurology, a group from Alnylam Pharmaceuticals used large-scale protein screening assays to simultaneously analyse many proteins in vast numbers of patient serum samples.

This approach allowed them to discover a novel biomarker of hereditary transthyretin-mediated (ATTRv) amyloidosis disease onset and progression.

ATTRv amyloidosis, caused by mutation of the transthyretin protein is a rare, adult-onset disease characterised by the accumulation of amyloid fibrils throughout the body, leading to progressive debilitation and death.

Olink is offering this article which looks at how to identify actionable biomarkers from the plasma proteome.

Download the article here.

 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free